Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Larimar Therapeutics
Research
FDA picks Denali, Neurogene and more for rare disease program
Four biotechs will get extra communication with agency officials in the FDA's "Operation Warp Speed" equivalent for rare disease.
Helen Floersh
Jun 4, 2024 2:51pm
Larimar's Friedreich's ataxia program free at last from FDA hold
May 21, 2024 9:55am
Stanford president resigns—Chutes & Ladders
Jul 21, 2023 9:30am
Larimar's limbo finally ends as FDA removes clinical hold
Sep 14, 2022 9:20am
Larimar still in limbo as company preps response to FDA hold
Aug 12, 2022 8:47am
Larimar in limbo as FDA maintains clinical hold
Feb 15, 2022 10:05am